Sonora Investment Management Group LLC cut its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 21.6% during the 4th quarter, according to its most recent Form 13F filing with the ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 11.26%, which has investors questioning if this is right time ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $60.6 which represents a slight increase of $0.93 or 1.56% from the prior close of $59.67. The stock opened at $60.08 and ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...